^
Association details:
| Biomarker: | DDB2 rs830083 |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Mylotarg (gemtuzumab ozogamicin) (DNA replication inhibitor, CD33-targeted antibody-drug conjugate) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Abstract 1921: The DDB2 intronic variation rs830083 is a strong predictor of gemtuzumab ozogamicin response in AML patients: A calicheamicin pathway-directed analysis from the COG-AAML0531 trial
Published date:
06/23/2020
Excerpt:
The intronic variation rs830083 (G>C) in DDB2 had the poorest outcome (OS Cox p = 0.01; EFS cox p = 0.004; DFS p = 0.000; RR reg p = 0.0006). Furthermore, rs830083 was also most significantly associated with standard risk patients (DFS p = 0.003), EFS (p=0.01) and RR (p = 0.0006)...Specifically, screening DDB2 SNPs could be applied in patient selection and predicting response to GO treatment.
DOI:
10.1158/1538-7445.AM2020-1921
